

Peer Review

Review of: "A Harmless Avian Vaccine Virus Could Be Developed into an Off-the-Shelf “Antibiotic” for Viruses"

Wattana Sukeepaisarnjaroen¹

1. Medicine, Khon Kaen University, Thailand

I agree with Dr. Tibor Bakacs to unlock the shelf-stocked R903/78 drug, but I am not sure about it and have the following concerns:

1. Naturally occurring infections of both types of viruses include hepatitis B and D infection, as well as hepatitis B and C infection. In the case of coinfection caused by hepatitis B and D infection, it means that there is an infection of both types of viruses at the same time, which has a good prognosis; there is a chance that hepatitis B will be cured and a low chance of chronic disease. However, many patients may die, which is like doing superinfection treatment in IBVD viral drug. If it doesn't cure, what will happen in the short term or long term? In contrast to superinfection, it means that there is a long-term infection of both viruses. This group of patients will have a high chance of chronic disease, and the prognosis is poor. It is comparable to doing superinfection treatment, which prolongs viremia, like IBVD viral drug in patients who did not recover after doing superinfection treatment. Therefore, in this group of patients, the outcome will be the same as superinfection in hepatitis B and D or not, which shows that the immune mechanism is still something to keep an eye on. Finally, is the immune cascade of IBVD viral drugs comparable to the coinfection and superinfection of HBV/HDV infection?

2. Since the origin of IBVD viral drug comes from animals, even if it is reverse engineered, it is still not comfortable for the control party because they are afraid of infection from animals to humans. Therefore, the data obtained from the research is small and not enough to be accepted. Therefore, we must wait for research in phase II/III. If humanity is lucky, we will study during the outbreak of viruses, both old groups such as Flu, Covid19, or new groups. We will get a lot of data and will be able to prove efficiency, effectiveness, and safety. I think we will have to wait for this data, not for 50 years. When we have positive data, and it is accepted by the regulatory authority, we may be able to include superinfection treatment (SIT) as one of the treatments for viral hepatitis.

Declarations

Potential competing interests: No potential competing interests to declare.